RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--June 21, 2006--Icagen, Inc. (NASDAQ: ICGN - News) today announced that the Company has recently met the seventy five percent point of enrollment in the Company’s pivotal Phase III trial of ICA-17043 for the chronic oral treatment of sickle cell disease, with 225 of the total expected study population of 300 patients now enrolled. The Company today also reaffirmed its prior guidance that it is targeting the second half of 2006 for the completion of enrollment and that it expects that the interim efficacy analysis will occur during the third quarter of 2006.
